Clinical Trials and Research for Women’s Cancers

The gynecologic oncology team at Froedtert & the Medical College of Wisconsin is involved with nationwide groups such as NRG and the GOG Foundation. These groups consist of Gynecologic Oncologists, Medical Oncologists, Pathologists, Radiation Oncologists, and many scientific researchers from around the US and the world.

NRG is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of our processes is utilized in order to constantly improve the quality of patient care.

To promote this mission, NRG receives support from the National Cancer Institute of the National Institutes for Health. General information on many of these trials for medical professionals and the lay public can be obtained from the NCI clinical trials database.

The GOG Foundation is a nonprofit organization dedicated to transforming the standard of care in gynecologic oncology, conducting clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva.

Clinical implications of research findings are disseminated to physicians and health-care professionals around the world, as well as to cancer survivors, their families, support groups, and advocates.

To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.

Open To Enrollment

Type of Cancer Protocol ID & Study Title
Any cancer being treated with carboplatin NRG-GY022
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Keywords: dMMR, DNA mismatch repair, Mismatch Repair Deficient, Early Stage, High Intermediate Rick, newly diagnosed, Pembrolizumab, Immunotherapy
Endometrial NRG-GY026
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma

Keywords: Endometrial cancer, HER-2 positive
Endometrial Sutro- STRO-002-GM1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Keywords: Advance Epithelial Ovarian Cancer, Fallopian Tube, Primary Peritoneal and Endometrial Cancer, Folate Receptor Alpha
Ovarian Springworks NIR-OGT-201
This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms, Granulosa cell tumor
Ovarian NRG-CC008
A Study to Compare Two Surgical Procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Keywords: BRCA1 Mutations, Salpingectomy, Oophorectomy
Ovarian, primary peritoneal, or fallopian tube cancer NRG-GY027
A Phase 1 study to test adding ipatasertib with the initial standard of chemotherapy, will have a better result in treating the patients with newly diagnosed ovarian cancer. The safety, side effects, and best dose of ipatasertib will also be determined in this study

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
Ovarian, primary peritoneal, or fallopian tube cancer GOG-3049-MER-XMT1536-3-UP-NEXT
Phase 3, multi-center randomized study of XMT-1536 (upifitamab rilsodotin) in patients with tumors expressing high levels of NaPi2b, focusing on patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer. This study will assess the progression free survival (the length of time that participants live without their disease getting worse) for participants with ovarian cancer with high NaPi2b.

Keywords: Ovarian cancer, platinum sensitive, recurrent cancer, randomized
Ovarian, primary peritoneal, or fallopian tube cancer GOG-3081-PRESERVE-004-MK3475

The study compares two doses of ONC-392 in combination with a fixed dose of pembrolizumab in participants with ovarian cancer who are resistant to platinum-based chemotherapy and have disease progression on line of therapy containing bevacizumab. Results from this study will be used to inform the study design, patient population, and dose selection for future studies in advanced ovarian cancer.

Keywords: Ovarian Cancer, Platinum Resistant, ONC-392
Ovarian, primary peritoneal, or fallopian tube cancer GOG-3073-CORT125134-556 / ROSELLA

This phase 3 study to test the effect of Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer. As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel. Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
Ovarian, primary peritoneal, or fallopian tube cancer STRO-002-GM2
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer Ovarian, primary peritoneal, or Fallopian Tube Cancer

Keywords: STRO-002, Phase 1, Bevacizumab, Refractory, Platinum Resistant, Dose Expansion, Anti-Folate Receptor Alpha Antibody Drug Conjugate, Advanced Epithelial Ovarian Cancer, Measurable Disease, High Grade Serous
Kidney transplant OBG-IIT-UYAR-HPV-MISP-61451

In this study, we want to learn how people with suppressed immune systems (e.g.-those undergoing an organ transplant) respond to HPV vaccine. We plan to study people who receive the vaccine before they undergo a kidney transplant and those who receive the vaccine after they undergo a kidney transplant to document the difference in the immune response to the vaccine compared to people who are not immune suppressed.

Keywords: Kidney Transplant, Immune Response, Vaccine, HPV